Arbutus Biopharma (ABUS) Debt Ratio (2016 - 2017)
Arbutus Biopharma (ABUS) posted Debt Ratio of 0.05 for Q4 2017, up 1.13% sequentially from 0.05 in Q3 2017, and up 16.34% YoY from 0.04 in Q4 2016.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Debt Ratio (2016 - 2017) Analysis & Trends
Arbutus Biopharma has reported Debt Ratio for 2 years, with the latest figure at 0.05 in Q4 2017.
- Quarterly Debt Ratio rose 16.34% year-over-year to 0.05 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was 0.05 (up 16.34% YoY) and the FY2017 annual result came in at 0.05, up 16.34% from the prior year.
- Debt Ratio advanced to 0.05 in Q4 2017 per ABUS's latest filing, from 0.05 in the prior quarter.
- Over five years, Debt Ratio peaked at 0.05 in Q4 2017 and troughed at 0.04 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 0.05 |
| Sep 30, 2017 | 0.05 |
| Jun 30, 2017 | 0.05 |
| Mar 31, 2017 | 0.04 |
| Dec 31, 2016 | 0.04 |